Review



nmda receptor antagonist mk801  (FUJIFILM)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    FUJIFILM nmda receptor antagonist mk801
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Nmda Receptor Antagonist Mk801, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nmda receptor antagonist mk801/product/FUJIFILM
    Average 90 stars, based on 1 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Rapid and cumulative adult plasticity in the mouse visual cortex"

    Article Title: Rapid and cumulative adult plasticity in the mouse visual cortex

    Journal: Frontiers in Neural Circuits

    doi: 10.3389/fncir.2025.1537305

    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with MK801 intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Figure Legend Snippet: NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with MK801 intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.

    Techniques Used: Knock-Out, MANN-WHITNEY, Injection



    Similar Products

    nmda receptor antagonist mk801  (MedChemExpress)
    95
    MedChemExpress nmda receptor antagonist mk801
    Nmda Receptor Antagonist Mk801, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nmda receptor antagonist mk801/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    non competitive nmda receptor antagonist mk801  (Tocris)
    96
    Tocris non competitive nmda receptor antagonist mk801
    Non Competitive Nmda Receptor Antagonist Mk801, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/non competitive nmda receptor antagonist mk801/product/Tocris
    Average 96 stars, based on 1 article reviews
    non competitive nmda receptor antagonist mk801 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    nmda receptor antagonist mk801  (FUJIFILM)
    90
    FUJIFILM nmda receptor antagonist mk801
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Nmda Receptor Antagonist Mk801, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nmda receptor antagonist mk801/product/FUJIFILM
    Average 90 stars, based on 1 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    nmda-type glutamate receptor antagonist mk801 (dizocilpine)  (FUJIFILM)
    90
    FUJIFILM nmda-type glutamate receptor antagonist mk801 (dizocilpine)
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Nmda Type Glutamate Receptor Antagonist Mk801 (Dizocilpine), supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nmda-type glutamate receptor antagonist mk801 (dizocilpine)/product/FUJIFILM
    Average 90 stars, based on 1 article reviews
    nmda-type glutamate receptor antagonist mk801 (dizocilpine) - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    glutamate nmda receptor antagonist mk801  (Tocris)
    97
    Tocris glutamate nmda receptor antagonist mk801
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Glutamate Nmda Receptor Antagonist Mk801, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glutamate nmda receptor antagonist mk801/product/Tocris
    Average 97 stars, based on 1 article reviews
    glutamate nmda receptor antagonist mk801 - by Bioz Stars, 2026-05
    97/100 stars
    		  Buy from Supplier
    nmda receptor antagonist mk801  (Tocris)
    97
    Tocris nmda receptor antagonist mk801
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Nmda Receptor Antagonist Mk801, supplied by Tocris, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nmda receptor antagonist mk801/product/Tocris
    Average 97 stars, based on 1 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-05
    97/100 stars
    		  Buy from Supplier
    nmda receptor antagonist mk801  (Biotrend Chemicals)
    90
    Biotrend Chemicals nmda receptor antagonist mk801
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Nmda Receptor Antagonist Mk801, supplied by Biotrend Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nmda receptor antagonist mk801/product/Biotrend Chemicals
    Average 90 stars, based on 1 article reviews
    nmda receptor antagonist mk801 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    mk801 hydrogen maleate mk 801 non competitive nmda receptor antagonist tocris  (Tocris)
    95
    Tocris mk801 hydrogen maleate mk 801 non competitive nmda receptor antagonist tocris
    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with <t>MK801</t> intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.
    Mk801 Hydrogen Maleate Mk 801 Non Competitive Nmda Receptor Antagonist Tocris, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mk801 hydrogen maleate mk 801 non competitive nmda receptor antagonist tocris/product/Tocris
    Average 95 stars, based on 1 article reviews
    mk801 hydrogen maleate mk 801 non competitive nmda receptor antagonist tocris - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with MK801 intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.

    Journal: Frontiers in Neural Circuits

    Article Title: Rapid and cumulative adult plasticity in the mouse visual cortex

    doi: 10.3389/fncir.2025.1537305

    Figure Lengend Snippet: NMDA receptor-dependent FVP (A) VEPs in NR2A knockout mice on days 1 and 6 (contralateral eye stimulation). (B) Absence of changes in VEP peaks (day 1 vs. day 6) in NR2A knockout mice after visual stimulation ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.5775; P1: p = 0.5844; N2: p = 0.4964. (C) VEPs of wild-type mice injected with MK801 intraperitoneally (0.5 mg/kg body weight) (day 1 vs. day 6, contralateral eye stimulation) 30 min before the start of visual stimulation. (D) Absence of FVP (day 1 vs. day 6) in MK801 treated wild type mice after visual stimulation. VEP peak N2 amplitudes ( N = 6 mice, 12 recording sites, 24 recordings of contralateral or ipsilateral eye stimulation). Mann–Whitney test, N1: p = 0.1305; P1: p = 0.4552, N2: p = 0.1060. (E) Impaired rapid potentiation in NR2A KO mice. Visual response (area under waveform) during the initial stimulation (0–10 pulses) vs. late stimulation (190–200 pulses) on day 1. Paired t -test, p = 0.924, 6 mice, t = 0.1002, df = 5.

    Article Snippet: The NMDA receptor antagonist MK801 (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) was dissolved in saline (0.1 mg/mL) and administered intraperitoneally (0.5 mg/kg) 15 min before daily recording sessions for 6 consecutive days.

    Techniques: Knock-Out, MANN-WHITNEY, Injection